tirzepatide results Before and after weight loss results: what real transformations look like and what determines success Achieve Your Weight Loss with

Total prescriptions reached approximately 1.3 million in Q1 2026 and have exceeded 2 million since launch, positioning the product as the strongest GLP-1 launch by volume in the U.S

A fresh vial with confirmed proper storage can help you determine if dosing needs to change or if the problem was storage all along

Notably, liraglutide (LEADER trial) and semaglutide (SUSTAIN-6 trial) have demonstrated cardiovascular benefits, including reductions in cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke

Results should be interpreted with your provider as part of a comprehensive clinical assessment